Skip to main content
Biotest AG logo

Biotest AG — Investor Relations & Filings

Ticker · BIO3 ISIN · DE0005227201 LEI · 529900JVX7RPXBLYUD89 F Manufacturing
Open in API
Filings indexed 1,148 across all filing types
Latest filing 2022-06-09 Regulatory Filings
Country DE Germany
Listing F BIO3

About Biotest AG

https://www.biotest.com/de/en/index.cfm

Biotest AG is a global company that develops, manufactures, and supplies plasma protein products and biotherapeutic drugs. Sourced from human blood plasma, its products are primarily used in the therapeutic areas of clinical immunology, haematology, and intensive care medicine. The portfolio includes immunoglobulins (e.g., Intratect), coagulation factors, and albumins designed to treat severe and chronic diseases such as immune deficiencies, haemophilia, and coagulation disorders. The company manages the entire value chain from clinical development to sales and is advancing a pipeline of new treatments, including next-generation immunoglobulins (BT595) and fibrinogen concentrates (BT524). Biotest also provides Human Serum Albumin for use as a multifunctional excipient in pharmaceutical and diagnostic applications.

Recent filings

Filing Released Lang Actions
Biotest AG: Biotest AG opens 11th plasma collection centre in Czech Republic
Regulatory Filings Classification · 100% confidence The document is a press release announcing a specific operational update: Biotest AG opening its 11th plasma collection centre in the Czech Republic. It is dated June 9, 2022, and is distributed via DGAP-News, which handles various corporate news. This type of announcement, detailing operational expansion and milestones that do not fit neatly into financial reporting (10-K, ER, IR), management changes (MANG), or capital structure events (CAP, SHA), is best classified as a general regulatory announcement or miscellaneous corporate news. Since it is not a formal financial report, a transcript, or a specific regulatory filing like DIRS or DIV, the most appropriate fallback category is Regulatory Filings (RNS), which covers general corporate news disseminated through official channels like DGAP.
2022-06-09 English
Jahresabschluss zum Geschäftsjahr vom 01.01.2021 bis zum 31.12.2021
Notice of Dividend Amount Classification · 95% confidence The document is a short announcement detailing the 'Gewinnverwendungsbeschluss' (resolution on the appropriation of profit) and the specific dividend amount per share approved at the Annual General Meeting. It provides the dividend payout details for the 2021 fiscal year. Since it focuses specifically on the declaration and breakdown of the dividend amount, it fits the 'Notice of Dividend Amount' category.
2022-06-08 German
Biotest AG: Biotest AG opens 10th plasma collection centre in Czech Republic
Regulatory Filings Classification · 100% confidence The document is a press release dated May 24, 2022, announcing a specific operational update: Biotest AG opening its 10th plasma collection centre in the Czech Republic. It contains company news, contact information, and is disseminated via DGAP (a service often used for regulatory news dissemination in Germany). This type of announcement, which is not a formal financial report (like 10-K, IR, ER) but rather a piece of corporate news regarding operations, does not fit neatly into the specific financial filing categories (like CAP, DIV, NAV). Since it is a general corporate announcement disseminated through a regulatory news service (DGAP), the most appropriate fallback category is Regulatory Filings (RNS), which covers miscellaneous regulatory announcements that don't fit elsewhere.
2022-05-24 English
Biotest AG: Dr Bernhard Ehmer new Chairman of the Supervisory Board of Biotest AG
Board/Management Information Classification · 98% confidence The document is a press release announcing a change in the Supervisory Board of Biotest AG, specifically naming the new Chairman, Dr. Bernhard Ehmer, following the Annual General Meeting (AGM). The key phrase is 'Dr Bernhard Ehmer new Chairman of the Supervisory Board of Biotest AG' and it explicitly mentions the 'Annual General Meeting'. This type of announcement, detailing changes in the board structure following an AGM, falls under Board/Management Information (MANG). While it relates to the AGM, it is a personnel announcement, not the AGM materials themselves (AGM-R) or the voting results (DVA).
2022-05-06 English
Report Publication Announcement 2022
Report Publication Announcement Classification · 100% confidence The document is titled "Preliminary announcement of the publication of financial reports according to Articles 114, 115, 117 of the WpHG". It explicitly states that it is announcing *when* and *where* future financial reports (specifically the 'Financial report of the group (half-year/Q2)' scheduled for August 11, 2022) will be disclosed. This fits the definition of a Report Publication Announcement (RPA), which covers announcements regarding the timing or release of company reports, rather than being the report itself. The document length is short (2104 chars), further supporting the RPA classification based on the 'MENU VS MEAL' rule.
2022-05-05 English
Biotest AG: Annual General Meeting approves dividend distribution
AGM Information Classification · 99% confidence The document explicitly states it is a 'PRESS RELEASE' regarding the 'Annual General Meeting approves dividend distribution'. It details resolutions passed at the AGM, including the dividend distribution (€ 0.04 per preferred share) and approval of management actions. This content directly relates to the outcomes and proceedings of the Annual General Meeting. While it mentions dividend distribution (DIV), the primary context is the meeting itself and its results. Since it is an announcement summarizing the AGM outcomes, the most specific category is AGM Information (AGM-R). It is not a DEF 14A (Remuneration) or a DIV (just the amount), but a summary of the meeting's key decisions.
2022-05-05 English

Browse filings by year

29 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.